Abstract Library

#2802 EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI)

Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Coriat R

Authors: Cadiot G, Coriat R, Raverot G, Nguyen Tan Hon T, Raingeard I,

Keywords: Octreotide LAR, NET, Acromegaly, Nurse,

#973 Toward a Preoperative Classification of Mesenteric Lymph Node Metastases for Better Selection of Carcinoid Tumors Before Radical Surgery

Introduction: Surgery for small bowel carcinoid (SBC) and lymph node (LN) metastases, when technically possible, represents the best therapy. However, surgical challenge is (i) not to recuse patients for false unresectable mesenteric artery invasion, and/or (ii) to avoid extensive small bowel resection.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Deguelte-Lardière S

Authors: Deguelte-Lardière S, Cadiot G, Appere F, Noaves M, Hentic O,

Keywords: carcinoid tumor, surgical procedures,

#916 PET+10 Study: Efficacy of Platin/Etoposide Combination in Well-Differentiated Pancreatic Neuroendocrine Tumors with Ki-67 ≥ 10%

Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: BAUDIN E

Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,

Keywords: platin/etoposide, pNETs, Ki-67,

#352 Predictive factors of tumor control in patients with well differentiated digestive endocrine carcinomas (WDEC) treated with lanreotide

Introduction: The antiproliferative effect of somatostatin analogs was recently demonstrated.

Conference:

Presenting Author:

Authors: Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V,

Keywords: somatostatin analogs, neuroendocrine, treatment, clinical,

#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide

Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Palazzo M, Catherine L, Guillaume C, Tamara M, Vinciane R,

Keywords: digestive endocrine tumors, lanreotide, tumor growth, Ki-67, liver metastases,